Which drug brands of oral factor b inhibitors are recognized for their effectiveness in united states?

Short answer: As of now, there are no FDA-approved oral Factor B inhibitors in the United States, so there are no recognized US brand names for this drug class.

Context:
- The leading oral Factor B inhibitor in development is iptacopan (formerly called LNP023) from Novartis. It is investigational and not yet approved by the FDA, so it does not have a US marketing brand name.
- If you’re looking for “brand names” of approved oral complement-targeting medicines in the US, those aren’t Factor B inhibitors. Examples include:
- Avacopan (brand name Tavneos) – an oral C5a receptor antagonist
- Pegcetacoplan (brand name Empaveli) – a C3 inhibitor (not Factor B)
- Eculizumab (Soliris) and Ravulizumab (Ultomiris) – IV C5 inhibitors

If you’re exploring treatment options, tell me the condition you’re interested in (e.g., PNH, GN, ANCA-associated vasculitis), and I can outline current approved therapies and the status of Factor B inhibitors in trials.